Policy Notices
General Notices
Notice of Changes to Funding Opportunities
Notices of Special Interest
Funding Opportunities
- Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R01 Clinical Trial Optional) (PAR-19-279)
National Cancer Institute
Application Receipt Date(s): July 15, 2019; November 15, 2019; July 15, 2020; November 15, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R21 Clinical Trial Optional) (PAR-19-280)
National Cancer Institute
Application Receipt Date(s): July 15, 2019; November 15, 2019; July 15, 2020; November 15, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)
(PAR-19-281)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): September 13, 2019; January 13, 2020; May 12, 2020; September 14, 2020 January 12, 2021; May 14, 2021; September 13, 2021; January 14, 2022; May 13, 2022, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
- Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
(PAR-19-282)
National Institute on Drug Abuse
Application Receipt Date(s): October 10, 2019; July 10, 2020; March 10, 2021; October 13, 2021; July 11, 2022; March 10, 2023, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional)
(PAR-19-283)
John E. Fogarty International Center
National Cancer Institute
National Institute on Drug Abuse
National Institute of Mental Health
Application Receipt Date(s): August 20, 2019; August 20, 2020; August 20, 2021, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (D71 Clinical Trial Not Allowed)
(PAR-19-284)
John E. Fogarty International Center
National Institute on Drug Abuse
National Institute of Mental Health
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below
- Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11 Clinical Trials Not Allowed)
(PAR-19-285)
John E. Fogarty International Center
National Institute on Drug Abuse
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
- PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional)
(RFA-DA-20-013)
National Institute on Drug Abuse
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
- Digital Health Technologies to Address the Social Determinants of Health in context of Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
(RFA-DA-20-017)
National Institute on Drug Abuse
Application Receipt Date(s): July 29, 2019, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Digital Health Technologies to Address the Social Determinants of Health in context of Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
(RFA-DA-20-018)
National Institute on Drug Abuse
Application Receipt Date(s): July 29, 2019, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Rapid Assessment of Drug Abuse: Smart City Tools (R41/R42 - Clinical Trial Optional)
(RFA-DA-20-020)
National Institute on Drug Abuse
Application Receipt Date(s): August 7, 2019, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Rapid Assessment of Drug Abuse: Smart City Tools (R43/R44 - Clinical Trial Optional)
(RFA-DA-20-021)
National Institute on Drug Abuse
Application Receipt Date(s): August 7, 2019, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Information Sharing System for State-Regulated Drug Compounding Activities (U01) Clinical Trial Not Allowed
(RFA-FD-19-025)
Food and Drug Administration
Application Receipt Date(s): July 17, 2019, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
- Centers Without Walls for Collaborative Research in the Epilepsies: Functional Evaluation of Human Genetic Variants (U54 Clinical Trial Not Allowed)
(RFA-NS-19-019)
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): August 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Sponsored Programs Administration Development (SPAD) Program (UC2 - Clinical Trial Not Allowed)
(RFA-RM-19-004)
Office of Strategic Coordination (Common Fund)
Application Receipt Date(s): July 25, 2019 and June 26, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
|
.png)
No hay comentarios:
Publicar un comentario